Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast

Endocrine-Related Cancer

Volumn 15, Issue 1, 2008, Pages 113-124

  Shibuya, Rie ^a   Suzuki, Takashi ^a   Miki, Yasuhiro ^a   Yoshida, Kimako ^a   Moriya, Takuya ^a   Ono, Katsuhiko ^a   Akahira, Jun Ichi ^a   Ishida, Takanori ^a   Hirakawa, Hisashi ^b   Evans, Dean B ^c   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOHOKU ROSAI HOSPITAL   (Japan)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; AROMATASE; ENZYME; ESTRADIOL; KI 67 ANTIGEN; MESSENGER RNA; SEX HORMONE; STEROID 5ALPHA REDUCTASE 1; STERYL SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE;

ADULT; AGED; ANDROGEN SYNTHESIS; ARTICLE; BREAST; BREAST CARCINOMA; BREAST SURGERY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CARCINOMA CELL; CARCINOMA IN SITU; ELECTROSPRAY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STROMA CELL; TANDEM MASS SPECTROMETRY;

17-HYDROXYSTEROID DEHYDROGENASES; ADULT; AGED; AGED, 80 AND OVER; AROMATASE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHROMATOGRAPHY, LIQUID; DIHYDROTESTOSTERONE; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STERYL-SULFATASE; STROMAL CELLS; SURVIVAL RATE;

EID: 41349105278     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/ERC-07-0092     Document Type: Article

References (49)

1. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML & Lanzino M 2002 Breast cancer: from estrogen to androgen receptor. Molecular and Cellular Endocrinology 193 121-128.
2. Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S & Sasano H 2000 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast. Anticancer Research 20 1101-1108.
3. Baqai T & Shousha S 2003 Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast. Histopathology 42 440-447.
4. Barnes NL, Boland GP, Davenport A, Knox WF & Bundred NJ 2005 Relationship between hormone receptor status and tumour size, grade and comedo necrosis in ductal carcinoma in situ. British Journal of Surgery 92 429-434.
5. Birrell SN, Bentel JM, Hickey TE et al. 1995 Androgens induce divergent proliferative responses in human breast cancer cell lines. Journal of Steroid Biochemistry and Molecular Biology 52 459-467.
6. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F & Pasqualini JR 2000 Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. Journal of Steroid Biochemistry and Molecular Biology 72 23-27.
7. Cuzick J 2003 Treatment of DCIS-results from clinical trials. Surgical Oncology 12 213-219.
8. Dauvois S, Geng CS, Levesque C, Merand Y & Labrie F 1991 Additive inhibitory effects of an androgen and the antiestrogen EM-170 on estradiol-stimulated growth of human ZR-75-1 breast tumors in athymic mice. Cancer Research 51 3131-3135.
9. Dumoulin FL, Nischalke HD, Leifeld L et al. 2000 Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. Journal of Immunological Methods 241 109-119.
10. Dunn BK, Wickerham DL & Ford LG 2005 Prevention of hormone-related cancers: breast cancer. Journal of Clinical Oncology 23 357-367.
11. Elston CW & Ellis IO 1991 Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer. Experience from a large study with long-term follow-up. Histopathology 19 403-410.
12. Faratian D, White S, Murray J et al. 2005 Effects of letrozole and anastrozole on ductal carcinoma in situ (DCIS): results from a randomised trial. Breast Cancer Research and Treatment 94 (Suppl 1) S262 (abstract 6041).
13. Franceschi S, Levi F, La VC, Randimbison L & Te VC 1998 Second cancers following in situ carcinoma of the breast. International Journal of Cancer 77 392-395.
14. Kandouz M, Lombet A, Perrot JY et al. 1999 Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. Journal of Steroid Biochemistry and Molecular Biology 69 463-471.
15. Kepple J, Henry-Tillman RS, Klimberg VS et al. 2006 The receptor expression pattern in ductal carcinoma in situ predicts recurrence. American Journal of Surgery 192 68-71.
16. Lapointe J & Labrie C 2001 Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology 142 4331-4338.
17. de Launoit Y, Dauvois S, Dufour M, Simard J & Labrie F 1991 Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11- [16′ alpha-chloro-3′, 17 beta-dihydroxy-estra-1′,3′, 5′-(10′)triene-7′ alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Research 51 2797-2802.
18. Li CI, Daling JR & Malone KE 2005 Age specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidemiology, Biomarkers and Prevention 14 1008-1011.
19. Miki Y, Suzuki T, Tazawa C, Yamaguchi Y, Kitada K, Honma S, Moriya T, Hirakawa H, Evans DB, Hayashi S et al. 2007 Aromatase localization in human breast cancer tissues: possible interactions between intratumoral stromal and parenchymal cells. Cancer Research 67 3945-3954.
20. Mistry P, Griffiths K & Maynard PV 1986 Endogenous C19-steroids and oestradiol levels in human primary breast tumour tissues and their correlation with androgen and oestrogen receptors. Journal of Steroid Biochemistry 24 1117-1125.
21. Moinfar F, Okcu M, Tsybrovskyy O et al. 2003 Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 98 703-711.
22. Namba R, Young LJ, Maglione JE et al. 2005 Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. Breast Cancer Research 7 R881-R889.
23. Niino YS, Irie T, Takaishi M et al. 2001 PKCtheta II, a new isoform of protein kinase C specifically expressed in the seminiferous tubules of mouse testis. Journal of Biological Chemistry 276 36711-36717.
24. Oliveira VM, Piato S & Silva MA 2006 Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium. Breast Cancer Research and Treatment 95 235-241.
25. Recchione C, Venturelli E, Manzari A, Cavalleri A, Martinetti A & Secreto G 1995 Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tissues. Journal of Steroid Biochemistry and Molecular Biology 52 541-546.
26. Reed MJ & Purohit A 2001 Aromatase regulation and breast cancer. Clinical Endocrinology 54 563-571.
27. Rody A, Diallo R, Poremba C et al. 2005 Androgen receptor expression in ductal carcinoma in situ of the breast: not a helpful marker for classification such as estrogen receptor alpha and progesterone receptor. Applied Immunohistochemistry and Molecular Morphology 13 25-29.
28. Ryde CM, Nicholls JE & Dowsett M 1992 Steroid and growth factor modulation of aromatase activity in MCF7 and T47D breast carcinoma cell lines. Cancer Research 52 1411-1415.
29. Selim AG, El-Ayat G & Wells CA 2002 Androgen receptor expression in ductal carcinoma in situ of the breast: relation to oestrogen and progesterone receptors. Journal of Clinical Pathology 55 14-16.
30. Silverstein MJ, Poller DN & Waisman JR 1995 Prognostic classification of breast ductal carcinoma in situ. Lancet 345 1154-1157.
31. Simpson ER & Davis SR 2001 Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. Endocrinology 142 4589-4594.
32. Sonne-Hansen K & Lykkesfeldt AE 2005 Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line. Journal of Steroid Biochemistry and Molecular Biology 93 25-34.
33. Spinola PG, Marchetti B, Merand Y, Belanger A & Labrie F 1988 Effects of the aromatase inhibitor 4-hydroxyandrostenedione and the antiandrogen flutamide on growth and steroid levels in DMBA-induced rat mammary tumors. Breast Cancer Research and Treatment 12 287-296.
34. Suzuki T, Moriya T, Ariga N, Kaneko C, Kanazawa M & Sasano H 2000 17β-Hydroxysteroid dehydrogenase type 1 and type 2 in human breast carcinoma: a correlation to clinicopathological parameters. British Journal of Cancer 82 518-523.
35. Suzuki T, Darnel AD, Akahira JI et al. 2001 5α-Reductases in human breast carcinoma: possible modulator of in situ androgenic actions. Journal of Clinical Endocrinology and Metabolism 86 2250-2257.
36. Suzuki T, Nakata T, Miki Y et al. 2003 Estrogen sulfotransferase and steroid sulfatase in human breast carcinoma. Cancer Research 63 2762-2770.
37. Suzuki T, Miki Y, Nakamura Y et al. 2005a Sex steroid-producing enzymes in human breast cancer. Endocrine-Related Cancer 12 701-720.
38. Suzuki T, Urano T, Tsukui T, Horie-Inoue K, Moriya T, Ishida T, Muramatsu M, Ouchi Y, Sasano H & Inoue S 2005b Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clinical Cancer Research 11 6148-6154.
39. Suzuki T, Miki Y, Moriya T et al. 2007 5α-Reductase type 1 and aromatase in breast carcinoma as regulators of in situ androgen production. International Journal of Cancer 120 285-291.
40. Tsikitis VL & Chung MA 2006 Biology of ductal carcinoma in situ classification based on biologic potential. American Journal of Clinical Oncology 29 305-310.
41. Vandesompele J, De Preter K, Pattyn F et al. 2002 Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biology 3 RESEARCH0034.
42. Vihko R & Apter D 1989 Endogenous steroids in the pathophysiology of breast cancer. Critical Reviews in Oncology/Hematology 9 1-16.
43. Warnberg F, Yuen J & Holmberg L 2000 Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355 724-725.
44. Yamashita K, Okuyama M, Watanabe Y, Honma S, Kobayashi S & Numazawa M 2007 Highly sensitive determination of estrone and estradiol in human serum by liquid chromatogaraphy-electrospray ionization mass spectrometry. Steroids 72 819-827.
45. Zhang Y, Kulp SK, Sugimoto Y, Farrar WB, Brueggemeier RW & Lin YC 1998 Keratinocyte growth factor (KGF) induces aromatase activity in cultured MCF-7 human breast cancer cells. Anticancer Research 18 2541-2546.
46. Zhang Z, Yamashita H, Toyama T et al. 2002 Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment 74 47-53.
47. Zhang J, Sun Y, Liu Y, Sun Y & Liao DJ 2004 Synergistic effects of androgen and estrogen on the mouse uterus and mammary gland. Oncology Reports 12 709-716.
48. Zhao Y, Agarwal VR, Mendelson CR & Simpson ER 1996 Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137 5739-5742.
49. Zhou J, Gurates B, Yang S, Sebastian S & Bulun SE 2001 Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Research 61 2328-2334.